Developments in renal pharmacogenomics and applications in chronic kidney disease [0.03%]
肾脏药物基因组学的研究进展及其在慢性肾病中的应用
Ariadna Padullés,Inés Rama,Inés Llaudó et al.
Ariadna Padullés et al.
Chronic kidney disease (CKD) has shown an increasing prevalence in the last century. CKD encompasses a poor prognosis related to a remarkable number of comorbidities, and many patients suffer from this disease progression. Once the factors ...
Laure Izquierdo,François Helle,Catherine François et al.
Laure Izquierdo et al.
Simeprevir (TMC435, Olysio™), a second-generation hepatitis C virus (HCV) protease inhibitor, has been recently approved for the treatment of genotype 1 chronic hepatitis C in combination with pegylated interferon and ribavirin. This molec...
Noura S Abul-Husn,Aniwaa Owusu Obeng,Saskia C Sanderson et al.
Noura S Abul-Husn et al.
Clinical genetic testing began over 30 years ago with the availability of mutation detection for sickle cell disease diagnosis. Since then, the field has dramatically transformed to include gene sequencing, high-throughput targeted genotypi...
Analytical strategies for discovery and replication of genetic effects in pharmacogenomic studies [0.03%]
药物基因组学研究中发现和验证遗传效应的分析策略
Jared R Kohler,Tobias Guennel,Scott L Marshall
Jared R Kohler
In the past decade, the pharmaceutical industry and biomedical research sector have devoted considerable resources to pharmacogenomics (PGx) with the hope that understanding genetic variation in patients would deliver on the promise of pers...
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways [0.03%]
乳腺癌新型治疗靶点的临床潜力：CDK4/6、Src、JAK/STAT、PARP、HDAC和PI3K/AKT/mTOR信号通路
Sarah R Hosford,Todd W Miller
Sarah R Hosford
Breast cancers expressing estrogen receptor α, progesterone receptor, or the human epidermal growth factor receptor 2 (HER2) proto-oncogene account for approximately 90% of cases, and treatment with antiestrogens and HER2-targeted agents h...
Dysregulation of the homeobox transcription factor gene HOXB13: role in prostate cancer [0.03%]
HOXB13基因失调控与前列腺癌的关系
Brennan Decker,Elaine A Ostrander
Brennan Decker
Prostate cancer (PC) is the most common noncutaneous cancer in men, and epidemiological studies suggest that about 40% of PC risk is heritable. Linkage analyses in hereditary PC families have identified multiple putative loci. However, unti...
MicroRNA binding site polymorphisms as biomarkers in cancer management and research [0.03%]
微小核糖核酸结合位点多态性作为癌症诊疗和研究的生物标志物
Monica Cipollini,Stefano Landi,Federica Gemignani
Monica Cipollini
MicroRNAs (miRNAs) are important regulators of eukaryotic gene expression. They have been implicated in a broad range of biological processes, and miRNA-related genetic alterations probably underlie several human diseases. Single nucleotide...
CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples [0.03%]
人正常结肠和正常肝脏样本中的细胞色素P450家族19亚族A成员1单核苷酸多态性与细胞色素P450家族19亚族A成员1、NFκB1和IL6基因表达的关系
Rosalind B Penney,Abbie Lundgreen,Aiwei Yao-Borengasser et al.
Rosalind B Penney et al.
Background: Estrogen is known to decrease the risk of colon cancer in postmenopausal women, and may exert its actions by decreasing interleukin-6 (IL6) production via stabilization of the transcription factor nuclear fact...
Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties [0.03%]
选择性专科医师的药物基因体知识差距和教育需求
Katherine A Johansen Taber,Barry D Dickinson
Katherine A Johansen Taber
Background: The use of pharmacogenomic testing in the clinical setting has the potential to improve the safety and effectiveness of drug therapy, yet studies have revealed that physicians lack knowledge about the topic of...
Targeting metastatic colorectal cancer - present and emerging treatment options [0.03%]
转移性结直肠癌的治疗选择：现状与前景
Kristen K Ciombor,Jordan Berlin
Kristen K Ciombor
Metastatic colorectal cancer is a significant cause of morbidity and mortality in the US and around the world. While several novel cytotoxic and biologic therapies have been developed and proven efficacious in the past two decades, their op...